Scinai Immunotherapeutics
SCNI
5 hedge funds and large institutions have $177K invested in Scinai Immunotherapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
64% less capital invested
Capital invested by funds: $495K → $177K (-$318K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$69.5K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$61.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$272K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$82K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.31K |
| 4 |
Citigroup
New York
|
-$1.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
1
Vantage Investment Advisors
State College,
Pennsylvania
| $62K | +$69.5K | +170 | New |
|
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $55K | +$61.3K | +150 | New |
|
|
3
Jane Street
New York
| $46K | -$272K | -666 | -84% |
|
|
4
UBS Group
Zurich,
Switzerland
| $13K | +$3.68K | +9 | +35% |
|
|
5
Citigroup
New York
| $1K | -$1.63K | -4 | -57% |
|
|
VKH
6
Virtu KCG Holdings
New York
| – | -$82K | -165 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$5.31K | -13 | Closed |
|
SCNI Hedge Fund Activity: Q3 2015 in Review
5 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2015, worth a combined $177K — down 64% from $495K a quarter earlier.
Fund positioning in SCNI was balanced in Q3 2015: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Vantage Investment Advisors, opening a new position worth an estimated $69.5K. The largest seller was Jane Street, cutting an estimated $272K.
- 5 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $177K of Scinai Immunotherapeutics stock for Q3 2015, down 64% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q3 2015 and 2 closed out, a net change of 0 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2015 was Vantage Investment Advisors, an estimated $69.5K added.
- The largest Scinai Immunotherapeutics seller in Q3 2015 was Jane Street, an estimated $272K sold.
Based on aggregated 13F filings for Q3 2015.